Hepatitis C (HCV) therapy has never been better. The latest data show sustained viral response rates (SVR) of 96 percent across the general population, while tweaks to existing regimens and new agents promise to bring SVRs closer to 100 percent. A panel of experts discussed the prospects for new HCV treatments during an AASLD symposium at DDW 2016.
The Affordable Care Act (ACA) was intended to improve access to health coverage and the way care is delivered and paid for in the U.S. President Obama’s signature legislation has already driven the uninsured rate below 10 percent, but changes in care delivery and payment are just beginning.
Top 10 social highlights from Monday’s exciting sessions and events. We’re looking forward to the final day of DDW and the remaining social buzz.
A new wave of research into the pathogenesis and natural history of cholestatic liver diseases is beginning to produce clinical results, according to Elizabeth J. Carey, MD, who will co-moderate Tuesday’s AASLD Clinical Symposium ‘Update on Cholestatic Liver Disease.’ Dr. Carey and co-moderator Christopher L. Bowlus, MD, provide a preview of the session.
AASLD and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) are co-sponsoring a special clinical symposium on Tuesday afternoon titled ‘The Intestinal Microbiome and Pediatric Liver Disease.’
Day 2 is in the books. See the highlights from today’s sessions included on social media using #DDW16.
A panel of experts will discuss the latest surveillance options, liver transplantation rules and immunotherapy guidelines for the treatment of hepatocellular carcinoma (HCC) during an AASLD Clinical Symposium Tuesday morning titled ‘Hepatocellular Cancer.’ The session’s moderators, including Lewis R. Roberts, MB, ChB, PhD, offer a preview.